Last reviewed 2026-06-01 · How we verify

Benzcyclan (BENCYCLANE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Benzcyclan (generic name: BENCYCLANE) is a bencyclane drug. It is currently in Phase 2 development for Cerebrovascular disease.

Bencyclane works by relaxing blood vessels and improving blood flow to the brain.

Benzcyclan is a small molecule with the synonyms BENCICLANO, BENCYCLANE, and BENCYCLANE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BENCYCLANE
Drug class	bencyclane
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Imagine your brain is like a garden that needs water to grow. Bencyclane helps to open up the 'pipes' that bring water to the garden, making it easier for the brain to get the blood it needs. This can help to prevent damage to the brain and improve symptoms of cerebrovascular disease.

Approved indications

Cerebrovascular disease

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Benzcyclan CI brief — competitive landscape report
Benzcyclan updates RSS · CI watch RSS

Frequently asked questions about Benzcyclan

What is Benzcyclan?

Benzcyclan (BENCYCLANE) is a bencyclane drug, indicated for Cerebrovascular disease.

How does Benzcyclan work?

Bencyclane works by relaxing blood vessels and improving blood flow to the brain.

What is Benzcyclan used for?

Benzcyclan is indicated for Cerebrovascular disease.

What is the generic name of Benzcyclan?

BENCYCLANE is the generic (nonproprietary) name of Benzcyclan.

What drug class is Benzcyclan in?

Benzcyclan belongs to the bencyclane class. See all bencyclane drugs at /class/bencyclane.

What development phase is Benzcyclan in?

Benzcyclan is in Phase 2.

Drug class: All bencyclane drugs
Therapeutic area: All drugs in Hematology
Indication: Drugs for Cerebrovascular disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing